MVI's mission is to accelerate malaria vaccine development and ensure availability in developing countries. Its goal is an 80% effective vaccine lasting 4+ years by 2025. Malaria infects 250 million people annually and kills 900,000, mostly children in Africa. Vaccine development faces challenges due to the parasite's complexity and limited commercial markets. MVI partners with organizations to systematically develop promising approaches through clinical trials. Its current strategy focuses on pre-erythrocytic, transmission-blocking, and P. vivax vaccines. With a phase 3 trial underway, MVI's public-private model brings malaria vaccines closer to reality.
![MVI mission, vision, and goal ,[object Object],[object Object],[object Object],MVI was established in 1999 as a program of PATH, an international nonprofit organization that creates sustainable, culturally relevant solutions, enabling communities worldwide to break longstanding cycles of poor health.](data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7)